Your browser doesn't support javascript.
Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.
Carrat, Fabrice; de Lamballerie, Xavier; Rahib, Delphine; Blanché, Hélène; Lapidus, Nathanael; Artaud, Fanny; Kab, Sofiane; Renuy, Adeline; Szabo de Edelenyi, Fabien; Meyer, Laurence; Lydié, Nathalie; Charles, Marie-Aline; Ancel, Pierre-Yves; Jusot, Florence; Rouquette, Alexandra; Priet, Stéphane; Saba Villarroel, Paola Mariela; Fourié, Toscane; Lusivika-Nzinga, Clovis; Nicol, Jérôme; Legot, Stephane; Druesne-Pecollo, Nathalie; Esseddik, Younes; Lai, Cindy; Gagliolo, Jean-Marie; Deleuze, Jean-François; Bajos, Nathalie; Severi, Gianluca; Touvier, Mathilde; Zins, Marie.
  • Carrat F; Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • de Lamballerie X; Département de Santé Publique, APHP.Sorbonne Université, Paris, France.
  • Rahib D; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.
  • Blanché H; Santé publique France, Saint-Maurice, France.
  • Lapidus N; Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.
  • Artaud F; Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Kab S; Département de Santé Publique, APHP.Sorbonne Université, Paris, France.
  • Renuy A; CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France.
  • Szabo de Edelenyi F; Paris University, Paris, France.
  • Meyer L; Paris-Saclay University, Inserm UMS 11, Villejuif, France.
  • Lydié N; Paris University, Paris, France.
  • Charles MA; Paris-Saclay University, Inserm UMS 11, Villejuif, France.
  • Ancel PY; Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France.
  • Jusot F; Université Paris-Saclay, Inserm, CESP U1018, Le Kremlin Bicêtre, France.
  • Rouquette A; Service de Santé Publique, APHP.Paris Saclay, Le Kremlin Bicêtre, France.
  • Priet S; Santé publique France, Saint-Maurice, France.
  • Saba Villarroel PM; Ined, Inserm, EFS, UMS Elfe, Aubervilliers, France.
  • Fourié T; Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité, Inserm U1153, Paris Descartes University, Paris, France.
  • Lusivika-Nzinga C; Clinical Research Unit, Center for Clinical Investigation P1419, Cochin Broca Hôtel-Dieu Hospital, Paris, France.
  • Nicol J; Université Paris-Dauphine, PSL-Research University, LEDa, Paris, France.
  • Legot S; Université Paris-Saclay, Inserm, CESP U1018, Le Kremlin Bicêtre, France.
  • Druesne-Pecollo N; Service de Santé Publique, APHP.Paris Saclay, Le Kremlin Bicêtre, France.
  • Esseddik Y; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.
  • Lai C; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.
  • Gagliolo JM; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.
  • Deleuze JF; Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Bajos N; Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Severi G; Paris University, Paris, France.
  • Touvier M; Paris-Saclay University, Inserm UMS 11, Villejuif, France.
  • Zins M; Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France.
Int J Epidemiol ; 50(5): 1458-1472, 2021 Nov 10.
Article in English | MEDLINE | ID: covidwho-1320316
ABSTRACT

BACKGROUND:

We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors.

METHODS:

Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies.

RESULTS:

The analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI) 9.1%, 10.9%] and 11.4% (95% CI 10.1%, 12.8%) in IDF, 9.0% (95% CI 7.7%, 10.2%) and 9.8% (95% CI 8.1%, 11.8%) in GE and 3.1% (95% CI 2.4%, 3.7%) and 2.9% (95% CI 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI 1.79, 6.09) in <40 vs 50-60 years old and OR = 0.56 (95% CI 0.42, 0.74) in ≥70 vs 50-60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI 0.57, 0.89)].

CONCLUSIONS:

Seropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Child / Humans / Middle aged Country/Region as subject: Europa Language: English Journal: Int J Epidemiol Year: 2021 Document Type: Article Affiliation country: Ije

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Child / Humans / Middle aged Country/Region as subject: Europa Language: English Journal: Int J Epidemiol Year: 2021 Document Type: Article Affiliation country: Ije